OKYO Pharma's Urcosimod Shows Promising NCP Pain Relief in Phase 2a Trial

Event summary

  • OKYO Pharma's abstract on urcosimod for neuropathic corneal pain (NCP) accepted for ARVO 2026 Annual Meeting (May 3-7, 2026).
  • Phase 2a trial of urcosimod showed clinically meaningful pain reduction and quality-of-life improvements in NCP patients.
  • Urcosimod demonstrated potential to restore corneal nerve structure in NCP patients.
  • Company plans to initiate a larger Phase 2b/3 trial with ~150 patients in the first half of 2026.

The big picture

OKYO Pharma's positive Phase 2a results for urcosimod in NCP mark a significant step in addressing a chronic, debilitating condition with no approved therapies. The upcoming Phase 2b/3 trial and ARVO presentation will be critical in validating the drug's potential and attracting partners or investors. The biopharmaceutical company is now poised to capitalize on the growing demand for innovative treatments in ophthalmology, particularly for conditions with high unmet medical needs.

What we're watching

Clinical Validation
Whether the Phase 2b/3 trial can replicate and expand on the positive results seen in the Phase 2a trial.
Regulatory Pathway
The pace at which the FDA will review urcosimod, given its Fast Track designation and the unmet need in NCP.
Market Potential
How OKYO Pharma positions urcosimod in a market with no FDA-approved treatments for NCP.